Stocks · News reference
Moleculin Biotech shares are trading higher after the company announced new preclinical data indicating that the antitumor activity of its lead drug candidate, Annamycin, in pancreatic cancer is partially mediated by CD8+ T cell cytotoxicity.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Moleculin Biotech, Inc. (MBRX)
Filed: 2026-10-20 AccNo: 0001437749-26-032969 Size: 313 KB Item 3.03: Material Modifications to Rights of Security Holders Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Moleculin Biotech shares are trading lower after the company announced a 1-for-20 reverse stock split, effective October 20.
Moleculin Biotech Announces 1-For-20 Reverse Stock Split, Effective October 20